By Prescription Only –
JANUARY 12, 2020 – In a recent article for The Verge, writer Christina Couch explored the work of a group of researchers whose area of study is MDMA. They’re based at Columbia University, at the Neuropsychopharmacology Lab there. Dr. Carl Hart, author of several books and the Chair of Columbia University’s Department of Psychology is one of them — he’s repeatedly called for a science-based approach to drug policy. At the center of Couch’s article is Christopher Medina-Kirchner, a PhD student at Columbia with a very personal stake in his research — as a young man, he was jailed for selling marijuana and ecstasy. The work that Medina-Kirchner is doing now is intended to provide scientists with more information about MDMA’s effects on humans. Couch writes that much of the evidence that caused MDMA to be designated a Schedule I drug in the 1980s, a designation that indicates “the punitively harshest category reserved for drugs like heroin that are deemed to have no medical uses and a high potential for abuse,” was based on faulty or flat-out incorrect science.
